Bookmark

Add to MyYahoo RSS

Pharmasset News

News on Pharmasset (Ticker: VRUS) continually updated from thousands of sources around the net.

19 hrs ago | Seeking Alpha

Gilead Earnings Preview: Non-Sovaldi Sales Bogey May Be Unrealistic

Gilead Sciences, Inc. reports Q2 earnings tomorrow. Gilead is a biopharmaceutical company that develops and markets medicines for unmet needs.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health, Pharmaceuticals

Fri Jul 11, 2014

AlertNet

U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug

Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough treatment for hepatitis C, citing the expense to federal healthcare programs.

Comment?

Related Topix: Gilead Sciences, Biotech, Medicine, Healthcare Industry, Hepatitis, Health, US News, US Senate, Ron Wyden, Democrat, US Politics, Startups, Pharmaceuticals

Fri Jun 20, 2014

Seeking Alpha

Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms

Much has been made of Merck's $3.85B acquisition of Idenix. Guesses have been made as to the next hepatitis C acquisition.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Pharmaceuticals, Gilead Sciences, Hepatitis, Health, Social Software

Thu Jun 12, 2014

BioSpace

AbbVie And Johnson & Johnson Were In A Bidding War For Idenix...

In the new generation of hepatitis C treatment regimens, drugs called nucleotide analogs, or "nucs," are the golden ticket.

Comment?

Related Topix: Pharmaceuticals

Mon Jun 09, 2014

Seeking Alpha

Gilead Down On Merck Idenix Deal, But Little To Fear

Merck announced it would buy Idenix Pharmaceuticals today for $3.85 billion, or $24.50 per share.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Merck , Pharmaceuticals

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••